Efficacy and Toxicity Assessment of Different Antibody Based Antiangiogenic Drugs by Computational Docking Method
Table 1
FDA-approved different antibody based antiangiogenic drugs.
Drug (MW)
Drug target
Recommended dose (half-life)
Types of cancer that are recommended for treatment
Bevacizumab, available as Avastin (149 KD)
VEGF receptor
IV infusion of 5–10 mg/kg body wt. in every 2 or 3 weeks (~20 days)
Metastatic colon, colorectal, cervical and peritoneal cancer with std. CT; platinum rst. ovarian or fallopian tube cancer; metastatic HER2 negative breast cancer; renal carcinoma; first-line treatment of non-small-cell lung cancer; second-line treatment of glioblastoma, different types of hematological malignancies
Trastuzumab, available as Herceptin (145.5 KD)
HER-2
IV infusion of 2–8 mg/kg body wt. in every week (~28.5 days)
HER-2 overexpressing including ER/PR negative and node positive or negative breast cancer in combination with either anthracycline based (paclitaxel or docetaxel) or cisplatin and capecitabine or 5-fluorouracil or carboplatin chemotherapy; HER-2 positive metastatic gastric or gastroesophageal junction endocarcinoma without prior chemotherapy
